Author details

Full Name

Jan J Molenaar

Affiliation

ORCID

Career Start Year

1998

Papers

105

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37528411	Effective methods for bulk RNA-seq deconvolution using scnRNA-seq transcriptomes.	Genome Biol	2023
37832507	Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.		2023
37152023	Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.	Front Oncol	2023
37400763	Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS.	BMC Cancer	2023
37020198	The potential of PARP as a therapeutic target across pediatric solid malignancies.	BMC Cancer	2023
36895472	MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.	Front Oncol	2023
37015036	Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.	J Clin Oncol	2023
36549117	Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.		2023
37364231	Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.	JCO Precis Oncol	2023
37294309	Three-Dimensional Modeling of Solid Tumors and Their Microenvironment to Evaluate T Cell Therapy Efficacy InÂ Vitro.		2023
37540673	Two opposing gene expression patterns within ATRX aberrant neuroblastoma.	PLoS One	2023
35327440	High-Throughput Drug Library Screening in Primary -Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.	Biomedicines	2022
36182817	Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.	Eur J Cancer	2022
36237330	Chromosome 11q loss and <i>MYCN</i> amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.	Front Oncol	2022
35384159	Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.	Cancer Sci	2022
35689207	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.	Mol Cancer	2022
35857500	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.	Sci Adv	2022
35671543	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.	Eur J Cancer	2022
35916583	Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.	EMBO Mol Med	2022
35400598	A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children.	Clin Oncol (R Coll Radiol)	2022
36521927	Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.		2022
33885033	Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort.	Journal of Pediatric Hematology/Oncology	2022
34963094	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.	Eur J Cancer	2022
34479993	Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.	Proc Natl Acad Sci U S A	2021
32381579	The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia.	Haematologica	2021
34271056	Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells.	Journal of Biotechnology	2021
34108262	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.	Mol Cancer Ther	2021
34049929	G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.	Journal for ImmunoTherapy of Cancer	2021
33667892	High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia.	Translational Oncology	2021
33547074	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell.	Sci Adv	2021
33190064	Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses.	European Journal of Cancer	2021
33341446	The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.	European Journal of Cancer	2021
34575700	Î±Î²-T Cells Engineered to Express Î³Î´-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression.	J Pers Med	2021
34575646	Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies.	Journal of Personalized Medicine	2021
34503139	The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development.	Cancers	2021
34433038	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.	Cell Rep	2021
34373263	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.	Cancer Discov	2021
32846370	Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.	eBioMedicine	2020
35844991	Decitabine mildly attenuates -rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo-sensitizer.		2020
31736229	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.	Pediatric Blood and Cancer	2020
32224415	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.	Eur J Cancer	2020
32161258	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.	Nat Commun	2020
32934208	Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.	Nat Commun	2020
32653773	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.	Eur J Cancer	2020
33077751	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.	Scientific Reports	2020
33016930	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.	J Clin Invest	2020
30894746	Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.	Nature	2019
34036221	Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.	JCO Precis Oncol	2019
30538293	ALK positively regulates MYCN activity through repression of HBP1 expression.	Oncogene	2019
31300807	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours.	Nat Rev Cancer	2019